Skip to main content
    W

    WORK Medical Technology Group LTD Ordinary Shares (WOK)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.23
    +0.03 (+2.50%)

    Market Cap: $5.36M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    WORK Medical Technology Group LTD Ordinary Shares (WOK) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    WORK Medical Technology Group LTD Ordinary Shares reported revenue of $9.85M for the fiscal year ended Sep 30, 2025, down 14.4% from the year before. That year, net income was -$1.07M with a net margin of -10.9%, operating cash flow was $6.24M and free cash flow was $4.91M. The quarter ended Jun 30, 2026 had revenue of $5.41M and net income of -$3.41M.

    Revenue and Margins

    The operating margin was -25.3% in the fiscal year ended Sep 2025. Over the 5 years to Sep 2025, revenue fell from $52.53M, a compound annual decline of 28.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$9.85M-14.4%23.8%-25.3%-10.9%
    Sep 2024$11.51M-15.2%24.9%-32.1%-30.4%
    Sep 2023$13.57M-31.2%30.5%3.6%0.8%
    Sep 2022$19.71M-57.0%22.4%9.3%4.4%
    Sep 2021$45.86M-12.7%18.8%16.7%13.0%
    Sep 2020$52.53MN/A20.7%11.4%2.2%
    Annual, fiscal years ended Sep 2020 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020
    Revenue$9.85M$11.51M$13.57M$19.71M$45.86M$52.53M
    Cost of revenue$7.50M$8.64M$9.42M$15.29M$37.22M$41.68M
    Gross profit$2.34M$2.87M$4.14M$4.42M$8.64M$10.85M
    Research and development$435.31K$302.51K$301.64K$183.90K$186.45K$797.38K
    Operating income-$2.50M-$3.70M$486.46K$1.82M$7.67M$5.99M
    Net income-$1.07M-$3.49M$112.03K$865.21K$5.96M$1.16M
    EBITDA$339.37K-$1.71M$2.08M$4.72M$11.87MN/A
    Fiscal years ended Sep 2020 to Sep 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$5.41M$5.31M$2.27M$4.54M$2.27M$6.20M$3.10M$5.31M$2.65M$4.55M$2.28M$9.01M
    Gross profit$530.35K$782.56K$781.15K$1.56M$781.15K$1.33M$662.70K$1.54M$771.49K$242.92K$121.46K$3.90M
    Operating income-$3.54M-$929.69K-$783.18K-$1.57M-$783.18K-$3.54M-$1.77M-$507.69K-$253.85K-$1.52M-$760.05K$2.01M
    Net income-$3.41M-$1.09M$6.58K$13.16K$6.58K-$3.72M-$1.86M$226.53K$113.26K-$1.36M-$681.85K$1.48M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, short-term debt of $6.41M exceeded cash and equivalents by $2.32M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020
    Total assets$33.16M$36.25M$29.96M$25.54M$30.66M$56.20M
    Current assets$20.46M$20.83M$22.15M$16.61M$18.15M$40.37M
    Cash and equivalents$4.09M$6.56M$1.60M$731.18K$508.71K$200.40K
    Total liabilities$11.99M$20.18M$18.97M$14.35M$19.26M$50.27M
    Short-term debt$6.41M$13.47M$9.05M$6.23M$6.60M$3.46M
    Long-term debtN/AN/AN/AN/AN/A$589.14K
    Shareholder equity$18.35M$13.19M$9.88M$10.00M$10.04M$4.90M
    Fiscal years ended Sep 2020 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$48.32M$48.31M$33.16M$33.16M$34.71M$34.71M$34.71M$36.25M$36.25M$32.49M$32.49M$29.96M
    Total liabilities$15.83M$15.83M$11.99M$11.99M$19.00M$19.00M$19.00M$20.18M$20.18M$21.16M$21.16M$18.97M
    Cash and equivalents$3.25M$3.25M$4.09M$4.09M$2.00M$2.00M$2.00M$6.56M$6.56M$1.04M$1.04M$1.60M
    Shareholder equity$30.13M$30.12M$18.35M$18.34M$12.95M$12.95M$12.95M$13.19M$13.19M$10.21M$10.21M$9.88M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Sep 2025, free cash flow was 78.7% of operating cash flow.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020
    Operating cash flow$6.24M-$2.23M$2.21M-$2.26M-$7.18M$27.20M
    Capital expenditures$1.33M$9.26M$583.30K$2.01M$60.00K$17.55M
    Free cash flow$4.91M-$11.49M$1.63M-$4.27M-$7.24M$9.65M
    Investing cash flow-$7.61M-$9.06M-$583.30K-$1.35M-$60.00K-$16.84M
    Financing cash flow-$898.21K$15.66M-$728.72K$3.57M$7.99M-$10.28M
    Fiscal years ended Sep 2020 to Sep 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$9.91M$9.04M-$2.80M-$5.59M-$1.40M-$963.40K-$481.70K-$1.26M-$632.34K$1.49M$745.14K$719.46K
    Capital expenditures$3.66M$1.09M$119.34K$238.68K$119.34K$9.20M$4.60M$28.78K$14.39K$83.24K$41.62K$666.54K
    Free cash flow-$13.57M$7.95M-$2.92M-$5.83M-$1.52M-$10.16M-$5.08M-$1.29M-$646.73K$1.41M$703.52K$52.92K
    Last 12 quarters

    Frequently Asked Questions About WOK

    What is WORK Medical Technology Group LTD Ordinary Shares' annual revenue?

    WORK Medical Technology Group LTD Ordinary Shares reported revenue of $9.85M for the fiscal year ended Sep 30, 2025.

    How fast is WORK Medical Technology Group LTD Ordinary Shares' revenue growing?

    Revenue was down 14.4% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -20.6%.

    Is WORK Medical Technology Group LTD Ordinary Shares profitable?

    No. WORK Medical Technology Group LTD Ordinary Shares reported net income of -$1.07M for the fiscal year ended Sep 30, 2025, with a net margin of -10.9%.

    How much free cash flow does WOK generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of $6.24M minus capital expenditures of $1.33M produced free cash flow of $4.91M.

    How much debt does WORK Medical Technology Group LTD Ordinary Shares have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $6.41M and cash and equivalents of $4.09M.